

Investor Newsletter

Issue **10** 2016



MicroPort® Concludes Enrollment in Randomized, Multicenter, European Study of Firehawk® Coronary Stent System

On October 17, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") announced that it has completed patient enrollment for its European clinical trial called TARGET All Comer ("TARGET AC") for its Firehawk® Rapamycin Target Eluting Coronary Stent ("Firehawk®"). The final patient to enroll in the TARGET AC clinical trial was enrolled by Dr. Niels van Royen of VU University Medical Center (VUmc), a university hospital affiliated with the VU University Amsterdam, in The Netherlands. The first patient for the TARGET AC clinical trial was enrolled in December 2015 by Dr. Lene Holmvang, Rigshospitalet University Hospital, Copenhagen, Denmark. With concerted efforts from all of the study investigators, the TARGET AC clinical trial met its objective to recruit and enroll a total of 1,656 patients, successfully accomplishing this objective in 10 months which was ahead of plan.

"The Firehawk® stent is a very conformable and deliverable stent that is well suited for treatment of complex lesion subsets," said William Wijns, M.D., PhD, Cardiovascular Research Center, OLV Aalst, Belgium, and principal investigator for the study. "I am very pleased that the TARGET AC trial enrolled so quickly and look forward to the study results for this innovative stent which was designed for quick and optimal vessel healing. The innovative groove design and the absorbable polymer of the Firehawk® stent system has the potential to positively impact patient care by further reducing the risk of late adverse events and the need for device-mandated prolonged dual antiplatelet therapy, which is often associated with a higher risk of bleeding as well as increased patient treatment cost."



Firehawk®
Rapamycin
Target Eluting
Coronary Stent
System

MicroPort® Attends GW-ICC 2016

From October 13 to October 16, the 27th Great Wall International Congress of Cardiology ("GW-ICC 2016"), the 21st Annual Scientific Meeting of the International Society of Cardiovascular Pharmacotherapy ("ISCP"), International Congress of Cardiovascular Prevention and Rehabilitation 2016, the World Heart Failure Congress 2016 and Asia Pacific Heart Congress 2016 were held in China National Convention Center, with 17300 medical professionals in attendance. On October 14, MicroPort® attended the GW-ICC 2016, and hosted a symposium - "Chasing the Horizon: Integrated Cardiac Intervention Platform by MicroPort®", which attracted wide attention from the audience.

The MicroPort® symposium started with a speech by Professor Bo Xu – "Innovation in Intervention: From Firehawk® to Firesorb®", in which he introduced in detail the design structure and innovative concept of MicroPort® in-house developed Firehawk® and Firesorb®, the second-generation fully bioresorbable scaffold, and noted that the six-month follow-up data of Firesorb® FUTURE I Clinical Trial will be released on Transcatheter Cardiovascular Therapeutics 2016.



Themed on "Clinical Trial of VitaFlow™ Transcatheter Aortic Valve and Delivery System ("VitaFlow™")", Professor Wenzhi Pan Shared the 30-day follow-up results of VitaFlow™ large-scale clinical trial with 86 patients, including low incidence rate of adverse cases, exceptional valve performance, to further prove the safety and efficacy of MicroPort® VitaFlow™.

Meanwhile, during the congress, MicroPort® displayed several innovative products such as Firehawk®, VitaFlow™, Columbus® and domestically made pacemakers in a booth, which was highly recognized by people in attendance.

MicroPort® Wins Annual PMO Award of PMI (China)

MicroPort® was granted the Annual PMO (Project Management Office) Award and Project Management Award Finalist by PMI (Project Management Institute) on the PMI (China) Congress 2016 held from October 22 to October 23 in China National Convention Center in Beijing. It is the first time for MicroPort® to participate in the PMI award selection.



Themed on "Project Management – Embracing China Opportunity," the PMI (China) Congress 2016 aims to drive the global development of project management theory and practice, build the most valuable project management communication platform in Asia-Pacific, as well as improve organizational performance through project management adoption. During the congress, PMI (China) hosted the award ceremony for project management awards and PMO awards. MicroPort® was granted the "Annual PMO Award of the 2016 PMI (China) Project Management Award", and the project of Firehawk® was granted the "Finalist of the 2016 PMI (China) Project Management Award." The two awards MicroPort® won in the PMI (China) Congress 2016 mean its project management skill and experience are fully recognized by professionals.

PMI, one of the world's largest not-for-profit membership associations for the project management profession, has been administering the project management awards in China since 2010 to promote the development of the best project management adopters in China and honor the enterprises and projects that stand out for their project management profession.

Firehawk® Receives South Korea KGMP Certification

On October 10, MicroPort® announced that its in-house developed Firehawk® obtained the Korea Good Manufacturing Practice ("KGMP") from the Ministry of Food and Drug Safety ("MFDS") of South Korea.

According to statistics, South Korea ranks No.3 in Asia in the size of its medical device market, following Japan and China. In spite of the huge market, it is not easy for foreign companies to register medical devices in the South Korea market since they have to comply with strict quality system regulations required by the South Korean government. In November 2014, MicroPort® received the on-site inspection by the MFDS for its JIVE balloon product before its market launch in South Korea, and successfully passed the auditing to obtain the KGMP certification in December 2014.

As Firehawk® was granted the KGMP certification, it once again proved that MicroPort® quality system complies with the KGMP quality system regulations, and meanwhile it paves the way for Firehawk® to receive the regulatory approval in the South Korea market.

Firehawk®
Rapamycin
Target Eluting
Coronary Stent
System


Firehawk® Implantation in Pakistan Completed

On October 17, Firehawk® was successfully implanted in the Northwest General Hospital in Peshawar of North Pakistan, marking the first implantation of Firehawk® in Pakistan after it received approval from the Drug Regulatory Authority of Pakistan ("DRAP") on September 8.

Pakistan is the sixth most populous country in the world. Pakistani population has one of the highest risks of coronary heart disease in the world. In Pakistan, 30 to 40 percent of all deaths can be attributed to cardiovascular diseases. The coronary heart disease death in Pakistan has reached about 200,000 per year. Firehawk®'s first successful implantation in Pakistan signifies its official entry in the market, which is expected to offer more ideal solutions to local patients with cardiovascular diseases.



Firehawk®
Rapamycin
Target Eluting
Coronary Stent
System



MicroPort® Endovascular Attends ENDOVASCULOLOGY 2016

From October 13 to October 15, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the ENDOVASCULOLOGY 2016 in Shanghai and hosted a satellite meeting for academic exchange on endovascular aortic repair ("EVAR").

On October 15, MicroPort® Endovascular hosted a satellite meeting "Development of EVAR Techniques: From 'UNIBODY' to 'LOW PROFILE'," chaired by Professor Zhiqing Zhao of Changhai Hospital of the Second Military Medical University and Professor Jianhua Huang of Xiangya Hospital of Central South University, exchanging ideas with attended experts on the experience in clinical application of Aegis™ Bifurcated Stent-Graft System and Delivery System ("Aegis™") and Hercules™ Stent-Graft with Low Profile Delivery System ("Hercules™").

During the congress, MicroPort® Endovascular set up a booth with special areas for trying out simulators, displaying products and watching video, which attracted many domestic and international attendees to visit the booth, try out devices and inquire for product information.

FireMagic® Cool Catheter Obtains CFDA Approval

On October 13, Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP") obtained the registration certificate of China Food and Drug Administration ("CFDA") for its in-house developed FireMagic® Irrigated Ablation Catheter ("FireMagic® Cool Catheter").

Combined with radio frequency ablation device, FireMagic® Cool Catheter is indicated for use in treating ECG proven arrhythmia with definite clinical symptoms, including AVRT and AVNRT.

The catheter has a high-torque shaft with a deflectable curve section containing an array of the platinum electrodes. Tip deflection is controlled at the proximal end by a handle. The high-torque shaft also allows the plane of the curved tip to be rotated to facilitate accurate positioning of the catheter tip at the desired site. It is a unidirectional catheter with four specifications of different curved shapes to meet patients' requirements.


At the proximal end of the catheter, a saline input port with a standard luer servers to permit the injection of normal saline to irrigate the tip electrode. With connection to the irrigation pump, normal saline passes through the lumen of the catheter and come out from the saline irrigation holes at the surface of the tip electrode to irrigate and cool the ablation site, which to reach the purpose of deep ablation.

The CFDA approval of FireMagic® Cool Catheter signifies that the device officially enters in the China market to offer more choices to domestic patients.




MicroPort® EP Attends APHRS 2016

From October 12 to October 15, MicroPort® EP attended the 9th Asia Pacific Heart Rhythm Society Scientific Session ("APHRS 2016") with more than 500 experts from 50 countries in attendance. During its first appearance in the APHRS annual meeting, MicroPort® EP displayed several innovative devices including FireMagic® Cardiac RF Ablation Catheter, FireMagic® Irrigated Ablation Catheter, and EasyFinder™ Electrophysiology Diagnostic Catheter, which attracted wide attention from the attendees.



By engaging in international cooperation and academic exchange in APHRS 2016, MicroPort® EP increased its innovation capability and the awareness of its brand, which is expected to help promote its products to benefit more patients.



Columbus®


3D EP Navigation
System

MicroPort® EP Attends 2016 Academic Annual Meeting of the Cardiology Society of Guangdong Medical Association to Display **Columbus®**

From October 8 to October 9, MicroPort® EP attended the 2016 Academic Annual Meeting of the Cardiology Society of Guangdong Medical Association in Jiangmen of Guangdong Province.

It was the first time that MicroPort® EP attended this academic meeting, during which MicroPort® EP displayed its Columbus® 3D EP Navigation System ("Columbus®") and live broadcasted a procedure using Columbus®.

This successful live broadcasted procedure of Columbus® enabled more domestic electrophysiologists to have a better understanding in the domestic 3D electrophysiology navigation system and enhanced their confidence in its clinical performance, which would benefit more patients with arrhythmia.



Columbus®
3D EP Navigation
System

MicroPort® EP and MSC Attend 12th Biennial Congress of Chinese Society of Pacing and Electrophysiology

From September 23 to September 25, MicroPort® EP and MicroPort Sorin CRM (Shanghai) Co., Ltd. ("MSC") attended 12th Biennial Congress of Chinese Society of Pacing and Electrophysiology. In the congress, the two companies displayed innovative products such as Columbus® and hosted satellite meetings which attracted wide attention.

On September 23, MicroPort® EP hosted a satellite meeting themed "Columbus®: Navigation for the Heart" in which speakers shared the clinical outcome and application of Columbus® and PathBuilder™ Interatrial Septal Puncture, a new product of MicroPort® EP waiting for approval from CFDA.

Meanwhile, MSC hosted a satellite meeting, themed "Striving for Excellence – From SafeR to Disease Management," during the congress, in which the speakers to lecture on sleep apnea monitor ("SAM") and SafeR functions of cardiac pacing devices, which was well received by attendees.



Dongguan Kewei Attends First Annual Meeting of China Extracorporeal Life Support Association

From October 14 to October 16, Dongguan Kewei Medical Instrument Co., Ltd. ("Dongguan Kewei"), a wholly owned subsidiary of MicroPort®, attended the First Annual Meeting of China Extracorporeal Life Support Association in Beijing.

During the meeting, Dongguan Kewei staff exchanged ideas with the congress chairman, vice-chairman and other experts about the future development of the domestic extracorporeal circulation industry. The attended experts highly recognized the achievements of Dongguan Kewei, and offered suggestions to its future product R&D.



Dongguan Kewei Recognized as "Company with Patent Advantage" in 2016 by Local Government

On September 30, Dongguan Kewei was recognized as one of the local companies with patent advantages in 2016 by Dongguan Science and Technology Bureau. Such honor represents recognition and support from the government, and will greatly elevate the brand value.

Since establishment, Dongguan Kewei has laid emphasis on in-house R&D and intellectual property protection. Several of its key products were counted as provincial-level key new products, new- and high-technology products, and Guangdong independent innovative products, and were granted provincial-level science and technology progress award. Up to date, it has 47 authorized patents, among which 9 are invention patents, 23 are utility model patents, and 15 are design patents.

MSC Displays Innovative Devices at 2016 Innovation Week Expo

MSC recently attended the Shanghai Venue of 2016 National Mass Entrepreneurship and Innovation Week ("Innovation Week") that kicked off on October 12, and display several innovative products.

During the exhibition, MSC's products attracted wide attention from the attendees. Shanghai Deputy Mayor Bo Zhou and his team also visited the MSC exhibition area, and showed great interest in the products and said he looked forward to the market launch of the domestically made pacemakers and pacing leads.



Investor Newsletter

Issue **10** 2016



For more information, please contact:

Martin Sun

Chief Financial Officer
MicroPort Scientific Corporation

Tel: (86)(21) 38954600

Email: ir@microport.com

Leanne Li

Board Secretary & Senior Director of External Affairs
MicroPort Scientific Corporation

Tel: (86)(21) 38954600

Email: ir@microport.com